The efficacy and safety of dupilumab combined with methylprednisolone in the treatment of bullous pemphigoid in China

Article Immunology

Association between TH2 Cytokine Gene Polymorphisms and Risk of Bullous Pemphigoid

Pardis-Sadat Tabatabaei-Panah et al.

Summary: This study uncovers a possible association between Th2 cytokine genetic variations and susceptibility to bullous pemphigoid (BP), an autoimmune skin disease. The results suggest that IL-13 rs1800925 variation may be a protective genetic marker for the development of BP, and IL-4R rs1805010 and IL-13 rs20541 polymorphic genotypes are associated with BP susceptibility. These findings advance our understanding of the pathogenesis of BP and provide new insights for the development of therapeutic strategies.

IMMUNOLOGICAL INVESTIGATIONS (2022)

Add to Collection

Review Dermatology

Prominent Role of Type 2 Immunity in Skin Diseases-Beyond Atopic Dermatitis

Lina Belmesk et al.

Summary: Type 2 immunity, characterized by Th2 lymphocytes and cytokines, is crucial for host defense and wound healing. Eosinophilia and high IgE counts are hallmarks of type 2 inflammation, which has been extensively studied in skin diseases beyond atopic dermatitis.

JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2022)

Add to Collection

Review Immunology

Insights Into the Pathogenesis of Bullous Pemphigoid: The Role of Complement-Independent Mechanisms

Connor Cole et al.

Summary: Bullous pemphigoid is an autoimmune blistering disease caused by autoantibodies. While typically considered complement-mediated, recent evidence suggests complement-independent mechanisms may also contribute to tissue damage and blister formation, opening new perspectives for targeted treatments.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Review Medicine, General & Internal

Current and Innovated Managements for Autoimmune Bullous Skin Disorders: An Overview

Kuan-Yu Chu et al.

Summary: Autoimmune bullous skin disorders are a group of serious diseases characterized by the formation of blisters and erosions on the skin and mucosal membrane. Prompt and effective treatment is crucial. Glucocorticoids are commonly used as the first-line approach, but long-term use may lead to significant adverse effects. Therefore, other adjuvant therapies are necessary.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Immunology

Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid

S. Morteza Seyed Jafari et al.

Summary: Combination therapy with omalizumab and dupilumab showed a complete response in a patient with refractory BP, offering a potential treatment option for similar cases.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Dermatology

The New Era of Biologics in Atopic Dermatitis: A Review

Simon Schneider et al.

Summary: Atopic dermatitis is a prevalent inflammatory skin disorder that affects all age and ethnic groups. Systemic drugs, particularly new biologics, have significantly expanded therapeutic approaches for patients with moderate to severe AD in recent years.

DERMATOLOGY PRACTICAL & CONCEPTUAL (2021)

Add to Collection

Letter Dermatology